Key Highlights

  • Novartis shares traded higher following Phase 3 results for remibrutinib in multiple sclerosis.
  • The data showed a significant reduction in relapses and brain lesions compared to Sanofi's teriflunomide.
  • The results bolster Novartis's BTK inhibitor franchise.
  • The company separately halted rap-cel trials for autoimmune diseases after three patient fatalities linked to a rare immune response.

Novartis AG (NYSE: NVS) shares traded higher following Phase 3 results for remibrutinib in multiple sclerosis, which demonstrated a significant reduction in relapses and brain lesions compared to Sanofi's teriflunomide.

What Happened

While the data bolster Novartis's BTK inhibitor franchise, the company separately halted rap-cel trials for autoimmune diseases after three patient fatalities linked to a rare immune response.

Market Reaction

Shares rose as investors weighed the positive remibrutinib data more heavily than the separate halt of the rap-cel program, which affects a different part of Novartis's broader pipeline.

Outlook

Continued development of the BTK inhibitor Franchise following the remibrutinib data, alongside further disclosure on the rap-cel trial halt, are likely to remain relevant for Novartis's pipeline narrative going forward.